A comparison of the mechanism and protective effects on liver and distant organs on patients with hepatic carcinoma and cirrhosis after hepatectomy with inflow occlusion among different anesthetics

A comparison of the mechanism and protective effects on liver and distant organs on patients with hepatic carcinoma and cirrhosis after hepatectomy with inflow occlusion among propfol, dexmedetomidin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001530

Enrollment

Unknown

Registered

2011-03-21

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic cirrhosis, hepatic carcinoma

Interventions

Group AP:propofol+NS, not inflow occlusion

Group BD:propofol+dexmedetomidine, inflow occlus

Group AD:propofol+dexmedetomidine, not inflow occlus

Group BS:sevoflurane, inflow occlus

Group BP:propofol+NS, inflow occlusion

Group AS:voflurane, not inflow occlus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with hepatic carcinoma;aged18-70; both male and female; voluntarily signed the consent form and participate in the study informed consent.

Exclusion criteria

Exclusion criteria: 1) A previous history of liver or GastrointestinalSurgery; 2) Severe heart or pulmonary diseases pre-operation. For example, a history of myocardial infarction within six months, heart function grade III-IV (killip grade), severe COPD, poor pulmonary function; 3) Poor liver function, Child-pugh Grade stays at grade B or C after treatment, ICG residual rate of 15min over 15%; 4) Pregnant patients; 5) A history of drug addict; 6) Patient refuse to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
troponin-T, CK, CK-MB, LDH, AST, ALT, TBIL, ALB, garma-GT, BUN, Cr; D-, DAO, CD3, CD3/CD4, CD3/CD8; TNF-alpha, IL-6;Cirrhosis classification;	—

Countries

China

Contacts

Public ContactZhongxing Wang

doctorwzx@21cn.com+86 13600049116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026